# ProQuad Dose Selection Study (V221-011)(COMPLETED)

> **NCT00986232** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1551 (actual)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
- **BIOLOGICAL:** Comparator: M-M-R II
- **BIOLOGICAL:** Comparator: PUVV

## Key facts

- **NCT ID:** NCT00986232
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2000-04
- **Final completion:** 2000-09
- **Target enrollment:** 1551 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986232, "ProQuad Dose Selection Study (V221-011)(COMPLETED)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00986232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*